Sponsored by Epstein Becker & Green, P.C.
MedTech Metro is an intimate forum and networking series designed to showcase New York's bio/med technology before an audience of investors, business leaders and health care providers. This 2014 series will feature three companies seeking investment or partners and a keynote speaker at each event. MedTech is the hub of New York State's bioscience and medical technology industry. It is an active association of nearly 100 pharmaceutical, biotech and medical technology companies, their suppliers and service providers and research universities.
City of New York Early-Stage Life Sciences Funding Initiative, Eric J. Gertler, Executive Vice President and Managing Director, New York City Economic Development Corporation (NYCEDC)
Eric will be discussing the City of New York's Early-Stage Life Sciences Funding Initiative, which represents an unprecedented public-private partnership across world-class academic institutions, industry leaders, top-tier investors, and the philanthropic community. Established by the NYCEDC with at least $50 million in matching funds from top-tier venture capital partners including Celgene Corporation, GE Ventures, and Eli Lilly & Company, the funding partnership will deploy a minimum of $100 million and seeks to launch 15 to 20 breakthrough ventures by 2020.
- Thermal Gradient is a Rochester-based biotechnology company with proprietary technology that enables extremely rapid nucleic acid (DNA/RNA) testing. Through strategic partnerships and its own branded products, Thermal Gradient microfluidic devices, subsystems, and systems result in faster, smaller and less complex molecular diagnostic systems for use in health care, biodefense, biomedical research, environmental safety and other related fields. The company's present focus is in systems for infectious disease detection and therapeutic monitoring and on actively pursuing strategic alliances for other applications.
- iFyber is a specialty materials company with corporate offices and laboratories located in Ithaca, New York. The company has experience in the commercial advancement of new technologies that require modulating the interfacial chemistry of a variety of substrates that include textiles, implantable medical devices, microspheres, and porous membranes. iFyber's development capabilities have expanded to include specialty chemicals for topical wound care treatments. These capabilities are specifically being applied to the advancement of nitric oxide delivery for chronic wounds through the advancement of topical formulations and fiber based dressings. iFyber has further applied its materials development expertise to a novel hemostatic agent for the wound care market. The hemostatic agent development relies on the company's capabilities related to new polymer synthesis, compound formulation, and experimental/regulatory guided testing.
- Raland Therapeutics Inc. is a development stage company focused on biosensor systems for life sciences. Raland's proprietary technology is showcased in the CytoCommT Living Biosensor System, a real time monitoring system for biological signaling and cellular responses in oncology and other applications. The system transmits live data through the cloud to Raland's data acquisition and analysis software. Using this system, real time results are available to caregivers or researchers at their desk or in remote locations.
|5:00-5:45 p.m.||Registration / Cocktail and networking reception|
|5:45-6:00 p.m.||Introduction by Jessica Crawford, President, MedTech Association|
|6:00-6:45 p.m.||Presentations by:
Robert D. Juncosa, CEO, Thermal Gradient;
Eric Eisenhut, President, iFyber, LLC
Bill Rader, President and CEO, Raland Therapeutics Inc.
|6:45-7:00 p.m.||Introduction by:
Kamesh Nagarajan, Senior Vice President - Wealth Mgmt Senior Portfolio Manager, and International Client Advisor (ICA), Morgan Stanley
|7:00-7:30 p.m.||Eric J. Gertler, Executive Vice President and Managing Director, New York Center for Economic Transformation|
To register, please click here.
If you have questions about this briefing, please contact
Kiirsten Lederer at (212) 351-4668 or firstname.lastname@example.org.